Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements.

Javanmardi N, Fransson S, Djos A, Umapathy G, Östensson M, Milosevic J, Borenäs M, Hallberg B, Kogner P, Martinsson T, Palmer RH.

Genes Chromosomes Cancer. 2019 Jul 24. doi: 10.1002/gcc.22790. [Epub ahead of print]


Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.

Javanmardi N, Fransson S, Djos A, Sjöberg RM, Nilsson S, Truvé K, Kogner P, Martinsson T.

Sci Rep. 2019 Feb 18;9(1):2199. doi: 10.1038/s41598-018-37240-z.


MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Sci Signal. 2017 Nov 28;10(507). pii: eaam7550. doi: 10.1126/scisignal.aam7550.


Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.

Fransson S, Östensson M, Djos A, Javanmardi N, Kogner P, Martinsson T.

Int J Oncol. 2016 Mar;48(3):1103-16. doi: 10.3892/ijo.2016.3349. Epub 2016 Jan 19.


Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.


Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.


Emergence of new ALK mutations at relapse of neuroblastoma.

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, Pierron G, Lapouble E, Combaret V, Speleman F, de Wilde B, Djos A, Ora I, Hedborg F, Träger C, Holmqvist BM, Abrahamsson J, Peuchmaur M, Michon J, Janoueix-Lerosey I, Kogner P, Delattre O, Martinsson T.

J Clin Oncol. 2014 Sep 1;32(25):2727-34. doi: 10.1200/JCO.2013.54.0674. Epub 2014 Jul 28.


Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene.

Djos A, Fransson S, Kogner P, Martinsson T.

BMC Med Genet. 2013 Oct 2;14:102. doi: 10.1186/1471-2350-14-102.


Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, Martinsson T, Navarro S, Noguera R.

PLoS One. 2013;8(1):e53740. doi: 10.1371/journal.pone.0053740. Epub 2013 Jan 14.


The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Djos A, Martinsson T, Kogner P, Carén H.

Mol Cancer. 2012 Jun 13;11:40. doi: 10.1186/1476-4598-11-40.


Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.

Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B.

Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.


Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.

Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S, Martinsson T.

BMC Cancer. 2011 Feb 11;11:66. doi: 10.1186/1471-2407-11-66.

Supplemental Content

Support Center